Korobeynikov, Vladislav A. http://orcid.org/0000-0002-9127-292X
Lyashchenko, Alexander K. http://orcid.org/0000-0003-0629-0494
Blanco-Redondo, Beatriz http://orcid.org/0000-0003-0246-2893
Jafar-Nejad, Paymaan http://orcid.org/0000-0001-5176-739X
Shneider, Neil A. http://orcid.org/0000-0002-3223-7366
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Institute of Neurological Disorders and Stroke (5R01NS106236)
Article History
Received: 14 May 2021
Accepted: 5 November 2021
First Online: 24 January 2022
Competing interests
: P.J.-N. is employed by Ionis Pharmaceuticals, a for-profit company that develops ASO therapies. The other authors declare no competing interests.